Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation.

Nykolyszyn C, Granata A, Pagliardini T, Castagna L, Harbi S, Bouabdallah R, Vey N, Fürst S, Maisano V, Legrand F, Lemarié C, Calmels B, Chabannon C, Weiller PJ, Blaise D, Devillier R.

Bone Marrow Transplant. 2019 Sep 18. doi: 10.1038/s41409-019-0682-2. [Epub ahead of print]

PMID:
31534196
2.

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R.

Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8.

PMID:
31296423
3.

Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.

Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, Granata A, Maisano V, Pagliardini T, De Philippis C, Kogan M, Faucher C, Harbi S, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1810-1817. doi: 10.1016/j.bbmt.2019.05.017. Epub 2019 May 22.

PMID:
31128326
4.

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.

Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS.

Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112. [Epub ahead of print] No abstract available.

PMID:
31014144
5.

PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Berriolo-Riedinger A, Fornecker LM, André M, Meignan M.

Lancet Oncol. 2019 Apr;20(4):e190. doi: 10.1016/S1470-2045(19)30156-1. No abstract available.

PMID:
30942177
6.

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

Granata A, Fürst S, Bramanti S, Legrand F, Sarina B, Harbi S, De Philippis C, Faucher C, Chabannon C, Lemarie C, Calmels B, Mariotti J, Maisano V, Weiller PJ, Mokart D, Vey N, Bouabdallah R, Castagna L, Blaise D, Devillier R.

Bone Marrow Transplant. 2019 Mar 19. doi: 10.1038/s41409-019-0500-x. [Epub ahead of print]

PMID:
30890770
7.

[CAR-T cells: Lymphocytes that express a chimeric antigen receptor].

Chabannon C, Bouabdallah R, Fürst S, Granata A, Saillard C, Vey N, Mokart D, Fougereau E, Lemarie C, Mfarrej B, Blaise D, Calmels B.

Rev Med Interne. 2019 Aug;40(8):545-552. doi: 10.1016/j.revmed.2018.12.002. Epub 2019 Jan 25. French.

PMID:
30686549
8.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
9.

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients.

Pagliardini T, Harbi S, Fürst S, Castagna L, Legrand F, Faucher C, Granata A, Weiller PJ, Calmels B, Lemarie C, Chabannon C, Bouabdallah R, Mokart D, Vey N, Blaise D, Devillier R.

Bone Marrow Transplant. 2019 Jul;54(7):1067-1076. doi: 10.1038/s41409-018-0387-y. Epub 2018 Nov 6.

PMID:
30401970
10.

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Xerri L, Adélaïde J, Avenin M, Guille A, Taix S, Bonnet N, Carbuccia N, Garnier S, Mescam L, Murati A, Chaffanet M, Coso D, Bouabdallah R, Bertucci F, Birnbaum D.

Histopathology. 2019 Mar;74(4):654-662. doi: 10.1111/his.13783. Epub 2019 Jan 31.

PMID:
30393995
11.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

12.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
13.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.

PMID:
30117149
14.

CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

Le KS, Amé-Thomas P, Tarte K, Gondois-Rey F, Granjeaud S, Orlanducci F, Foucher ED, Broussais F, Bouabdallah R, Fest T, Leroux D, Yadavilli S, Mayes PA, Xerri L, Olive D.

Blood Adv. 2018 Aug 14;2(15):1889-1900. doi: 10.1182/bloodadvances.2018017244.

15.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G.

Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.

16.

A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.

Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP.

J Invest Dermatol. 2018 Sep;138(9):1982-1989. doi: 10.1016/j.jid.2018.03.1516. Epub 2018 Mar 27.

17.

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.

Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E.

Ann Oncol. 2018 Mar 1;29(3):715-723. doi: 10.1093/annonc/mdx787.

PMID:
29253087
18.

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, Faucher C, Harbi S, Morabito L, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2018 Mar;24(3):627-632. doi: 10.1016/j.bbmt.2017.11.030. Epub 2017 Nov 29.

19.

CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.

Xerri L, Adélaïde J, Popovici C, Garnier S, Guille A, Mescam-Mancini L, Laurent C, Brousset P, Coze C, Michel G, Chaffanet M, Bouabdallah R, Coso D, Bertucci F, Birnbaum D.

Am J Surg Pathol. 2018 Feb;42(2):150-159. doi: 10.1097/PAS.0000000000000989.

PMID:
29194093
20.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
21.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant. 2017 Aug;52(8):1120-1125. doi: 10.1038/bmt.2017.88. Epub 2017 May 22.

PMID:
28530668
22.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):797. doi: 10.1038/bmt.2017.26. No abstract available.

PMID:
28465624
23.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B.

J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.

PMID:
28426350
24.

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G; a LYSA study.

Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.

PMID:
28414090
25.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Jul 10;35(20):2342.

PMID:
28355112
26.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.

J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.

PMID:
28291393
27.

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.

Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJS, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F.

Haematologica. 2017 May;102(5):903-909. doi: 10.3324/haematol.2016.154377. Epub 2017 Jan 25.

28.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):683-688. doi: 10.1038/bmt.2016.348. Epub 2017 Jan 16. Erratum in: Bone Marrow Transplant. 2017 May;52(5):797.

PMID:
28092347
29.

[Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].

Garciaz S, Coso D, Brice P, Bouabdallah R.

Bull Cancer. 2016 Dec;103(12):1035-1049. doi: 10.1016/j.bulcan.2016.10.011. Epub 2016 Nov 17. Review. French.

PMID:
27866679
30.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C.

Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262.

31.

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D.

Bone Marrow Transplant. 2016 Dec;51(12):1644-1646. doi: 10.1038/bmt.2016.257. Epub 2016 Oct 17. No abstract available.

PMID:
27748737
32.

A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety.

Poizot-Martin I, Brégigeon S, Tamalet C, Bouabdallah R, Zaegel-Faucher O, Obry-Roguet V, Ivanova A, Cano CE, Solas C.

Case Rep Oncol Med. 2016;2016:8515218. doi: 10.1155/2016/8515218. Epub 2016 Jul 20.

33.

Lenalidomide for the treatment of B-cell lymphoma.

Garciaz S, Coso D, Schiano de Colella JM, Bouabdallah R.

Expert Opin Investig Drugs. 2016 Sep;25(9):1103-16. doi: 10.1080/13543784.2016.1208170. Epub 2016 Jul 22. Review.

PMID:
27414850
34.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.

PMID:
27313086
35.

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L, Olive D.

Cancer Res. 2016 Aug 15;76(16):4648-60. doi: 10.1158/0008-5472.CAN-15-0589. Epub 2016 May 31.

36.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).

Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerm G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H.

Bone Marrow Transplant. 2016 Jul;51(7):928-32. doi: 10.1038/bmt.2016.76. Epub 2016 Apr 4.

PMID:
27042842
37.

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H.

Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24.

PMID:
27010483
38.

The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D.

Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21. No abstract available.

PMID:
26999460
39.

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W.

J Clin Oncol. 2016 Apr 20;34(12):1386-94. doi: 10.1200/JCO.2015.63.8387. Epub 2016 Feb 29.

PMID:
26926679
40.

First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation.

Perrin J, Saïas-Magnan J, Broussais F, Bouabdallah R, D'Ercole C, Courbiere B.

J Assist Reprod Genet. 2016 May;33(5):663-666. doi: 10.1007/s10815-016-0674-8. Epub 2016 Feb 9. No abstract available.

41.

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.

Bachy E, Estell JA, Van de Neste E, Bouabdallah R, Bargay J, Delmer A, Gelas-Dore B, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Lamy T, Dartigues P, Seymour JF, Salles G.

Am J Hematol. 2016 Jun;91(4):410-5. doi: 10.1002/ajh.24305.

42.

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P; Lymphoma Study Association (LYSA).

Haematologica. 2016 Apr;101(4):466-73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.

43.

Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.

Saillard C, El Cheikh J, Granata A, Coso D, Schiano JM, Bouabdallah R, Blaise D, Charrier N, Broussais F.

Leuk Lymphoma. 2016;57(3):714-6. doi: 10.3109/10428194.2015.1061190. Epub 2016 Jan 11. No abstract available.

PMID:
26750740
44.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P.

Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31.

45.

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Brière J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P.

Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24. No abstract available.

46.

Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.

Garciaz S, Harel S, Amorim S, Bouabdallah R, Thieblemont C, Brice P.

Br J Haematol. 2016 Nov;175(4):735-737. doi: 10.1111/bjh.13879. Epub 2015 Dec 18. No abstract available.

PMID:
26685097
47.

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.

Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H.

J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7.

48.

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, Scime R, Kobbe G, Ferrara F, Delmer A, Sayer H, Amorim S, Bouabdallah R, Finke J, Salles G, Yakoub-Agha I, Faber E, Nicolas-Virelizier E, Facchini L, Vallisa D, Zuffa E, Sureda A, Dreger P; EBMT Lymphoma Working Party.

Bone Marrow Transplant. 2016 Feb;51(2):212-8. doi: 10.1038/bmt.2015.273. Epub 2015 Nov 16.

PMID:
26569093
49.

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, Chabannon C, Helvig A, Xerri L, Blaise D, Bouabdallah R.

Bone Marrow Transplant. 2016 Feb;51(2):319-21. doi: 10.1038/bmt.2015.257. Epub 2015 Nov 2. No abstract available.

PMID:
26524266
50.

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.

El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.

Mediterr J Hematol Infect Dis. 2015 Aug 20;7(1):e2015048. doi: 10.4084/MJHID.2015.048. eCollection 2015.

Supplemental Content

Loading ...
Support Center